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Take-home message:  
High success rates for TB treatment were achieved in children and adolescents in The 
Netherlands. To further optimize care in this population, several risk factors particularly 
associated with mortality and lost to follow-up have been identified. 
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Background: As a vulnerable population, children and adolescents with tuberculosis (TB) 
are faced with many challenges, even for those who live in low TB incidence countries. We 
aimed to evaluate factors associated with TB treatment outcomes allowing more focused 
interventions to support this population once diagnosed. 
Methods: A retrospective cohort study using a nationwide surveillance database was 
performed in children and adolescents (0-18 years) treated for TB in The Netherlands from 
1993-2018. Logistic regression analyses were used to estimate adjusted odds ratios (aOR) 
for associated factors of mortality and lost to follow-up (LTFU). 
Results: Among 3253 eligible patients with known outcomes, 94.4% (95.9% children and 
92.8% adolescents) were cured or completed treatment, 0.7% died during treatment and 
4.9% were LTFU. There were no reported treatment failures. Risk factors of death included 
children aged 2-4 years (aOR=10.42), central nervous system TB (aOR=5.14), miliary TB 
(aOR=10.25), HIV coinfection (aOR=8.60), retreated TB cases (aOR=10.12), and drug-
induced liver injury (aOR=6.50). Active case-finding was a protective factor of death 
(aOR=0.13). Risk factors of LTFU were adolescents aged 15-18 years (aOR=1.91), illegal 
immigrants (aOR=4.28), urban domicile (aOR=1.59), unknown history of TB contact 
(aOR=1.99), drug-resistant TB (aOR=2.31), single adverse drug reaction (ADR) (aOR=2.12), 
multiple ADRs (aOR=7.84) and treatment interruption >14 days (aOR=6.93). Treatment in 
recent years (aOR=0.94) and supervision by public health nurses (aOR=0.14) were 
protective factors of LTFU. 
Conclusion: Highly successful treatment outcomes were demonstrated in children and 
adolescents routinely treated for TB. Special attention should be given to specific risk groups 
to improve treatment outcomes. 
Key words: Tuberculosis, treatment outcome, mortality, lost to follow-up, children, 
adolescent.  
INTRODUCTION 
Tuberculosis (TB) is a major global health problem with an estimated 1 million children who 
developed TB worldwide in 2017 [1]. Childhood TB has historically been given low priority in 
most national programmes because it contributes little to disease transmission. Similarly, 
adolescents are also faced with many challenges as they have been neglected in TB 
surveillance even when they suffer from a significant burden of the disease [2, 3]. Since the 
World Health Organization (WHO) published 10 key actions in 2013 as the first roadmap for 
childhood TB [4], significant progress has been made but gaps still remain especially on age- 
and disease-related challenges such as young children (<5 years), adolescents (10-19 
years), TB/HIV coinfection, and multidrug-resistant TB (MDR-TB). The 2018 WHO roadmap 
brings new hope of accelerating efforts towards ending TB in children and adolescents by 
ensuring them to receive high priority in all TB prevention and control activities [5]. 
As one of the top ten causes of death, childhood TB is a silent killer with the risk of 
mortality being particularly high in under-five children and HIV co-infected children not 
receiving antiretroviral therapy (ART) [6, 7]. In low-incidence countries like The Netherlands, 
TB elimination requires extensive but focused screening and prevention as the patients 
become more concentrated in certain vulnerable and high-risk groups such as the poor, 
immigrants, asylum seekers, homeless, prisoners, alcohol or drug addicts, and people living 
with HIV/AIDS [8]. Management of childhood and adolescent TB is still a pressing challenge 
even for low-incidence countries, particularly due to the lack of child-friendly drug 
formulations, difficulties in diagnosis and treatment of latent TB infection (LTBI) [9]. 
Few studies with large cohorts of children mostly from high-incidence settings in 
Africa have reported factors associated with TB treatment outcomes in children [10–14]. 
However, most of the variables analysed in these studies were relatively limited to 
demographic and clinical characteristics. Other potential confounders such as vaccination 
status, types of case-finding, drug-susceptibility of the TB strains, and other clinical-, 
bacteriological- and treatment-related factors have not been fully evaluated. Related data in 
both children and adolescents from low-incidence countries is also lacking. In this context, 
our study aimed to evaluate treatment outcomes and associated factors in children and 
adolescents routinely treated for TB in The Netherlands. This would allow for appropriate 
interventions to optimize TB care in this vulnerable population. 
METHODS 
Study design and data sources 
This retrospective cohort study was performed using surveillance data obtained from the 
Netherlands Tuberculosis Register (NTR). The NTR is a nationwide database for patients 
with TB and LTBI, managed by the Dutch National Institute for Public Health and the 
Environment (RIVM) in collaboration with 25 departments of the Municipal Public Health 
Services (MPHS) and the Royal Netherlands Tuberculosis Association (KNCV). Since 1993, 
data on disease notification, demographics, clinical, bacteriological, and treatment 
characteristics are recorded by the MPHS in all TB patients.  
Study population 
All children and adolescents (0-18 years) treated for TB between January 1993 and 
December 2018 were included in this study. Patients in ongoing treatment with incomplete 
data on treatment outcomes were excluded. 
Data collection 
The following individual data with anonymous identifiers were obtained from the NTR on 22 
May 2019: (1) demographics (year of diagnosis, age, gender, native/foreign-born, WHO 
region of birth, immigrant status, and area of living); (2) TB notification and clinical 
characteristics (types of case-finding, history of TB contact, travel history in TB endemic 
area, site and localisation of TB, cavitary TB, Bacillus Calmette-Guerin (BCG) vaccination, 
TB symptoms, patient’s and doctor’s delay in diagnosis and treatment, and comorbidity); (3) 
bacteriological characteristics (acid-fast bacilli (AFB) smear microscopy, mycobacterial 
culture, and drug susceptibility testing (DST)); and (4) treatment characteristics (previous 
history of TB/LTBI treatment, daily/intermittent dosing, presence of adverse drug reactions 
(ADRs), drug-induced liver injury (DILI), treatment interruption >14 days, hospitalisation, 
treatment supervision by public health nurses (PHNs) and implementation of directly 
observed therapy (DOT)). 
Definitions 
Age was generally divided into 2 groups: children <15 years and adolescents aged 15-18 
years. The cut-off of <15 years for children was used to be consistent with the age category 
used for reporting TB surveillance data nationally and by the WHO [1]. The upper age limit of 
18 years for adolescent TB was based on the definition used by the WHO European Region 
[15]. Active case-finding (ACF) was defined as the systematic screening for active TB cases 
in a predetermined high-risk group for TB, rather than waiting for patients who came on their 
own to the healthcare system because of TB symptoms (passive case-finding (PCF)). 
Pulmonary TB (PTB) included all forms of TB in the lungs, isolated tracheal or bronchus TB, 
laryngeal TB, and other specified respiratory TB. TB within other locations in the body than 
the lungs, including mediastinal lymphadenopathy, were classified as extrapulmonary TB 
(EPTB), which may have involved isolated EPTB or a combination of PTB and EPTB. 
Confirmed drug-susceptible TB (DS-TB) was defined as a susceptible result of DST for all 
first-line anti-TB drugs (isoniazid, rifampicin, pyrazinamide and ethambutol), while presumed 
DS-TB was defined as patients treated with first-line anti-TB drugs without sufficient 
information on DST. Patients with DST results of mono-resistant, poly-resistant, MDR, or 
XDR (extensively drug-resistant) were classified as confirmed drug-resistant TB (DR-TB). 
DILI due to anti-TB drugs was defined as an increased level of alanine aminotransferase >3x 
the upper limit of normal (ULN) in the presence of symptoms of hepatotoxicity or >5x the 
ULN in the absence of symptoms. Treatment supervision by PHNs was defined as 
supportive discussions with patients and their family to provide TB education and 
identification of obstacles that influence treatment adherence. DOT was defined as every 
dose of anti-TB drugs taken under direct observation for a period of time, provided by either 
PHNs or other selected third parties such as family members or home nursing services. 
Operational definitions for all variables are shown in Supplementary Table 1 [16, 17]. 
 
Outcomes 
Treatment outcomes (cured, treatment completed, died, treatment failed, lost to follow-up 
(LTFU), and not evaluated (unknown outcomes)) were defined based on the Dutch national 
guidelines for TB programmes and generally in accordance with the current WHO guidelines 
(Table 1) [16, 18].  
Data analysis 
Associations of patient characteristics with mortality and LTFU were evaluated. First, patients 
who died during treatment were compared to those who were alive at the end of treatment 
regardless of whether they were cured, completed or failed treatment; this definition excluded 
LTFU and unknown outcomes. Second, LTFU patients were compared to those who 
achieved cure or completed treatment with or without evidence of treatment failure; this 
definition excluded death and unknown outcomes. Given the possibility of selection bias from 
the exclusion of particular patients in the first and second analyses, additional outcome 
classification was created assessing patients who achieved cure or completed treatment 
(favourable) compared to all other outcomes (unfavourable).  
 Univariate and multivariate logistic regression analyses were used to evaluate the 
association between candidate variables and treatment outcomes. All variables in the 
univariate analysis showing a trend towards association with each of the evaluated 
outcomes, and with a minimum number of 20 patients in any particular group of predictors, 
were eligible for inclusion in multivariate analysis and were selected using backward 
elimination. The final multivariate models retained all explanatory variables with a P-value 
<0.1. The Hosmer-Lemeshow test was used to evaluate the goodness-of-fit of the final 
models. The performance of the final models were measured by the area under the receiver 
operating characteristic (ROC) curve. Crude and adjusted odds ratios (OR) with 95% 
confidence intervals (CI) were used to estimate the association between explanatory 
variables and treatment outcomes. Statistical significance was accepted at P<0.05 whereas 
P-values of 0.05-0.10 were considered trends. All data were analysed with IBM SPSS 
Statistics version 25.0.  
 
Ethics 
Research approval was granted by the research committee of the NTR. As this was a 
retrospective study using routine data collected anonymously, ethics clearance and individual 
patient written informed consent were not required under Dutch law. 
RESULTS 
During a 26-year period from January 1993 to December 2018, 3442 TB cases in children 
and adolescents were notified: 46 patients in ongoing treatment were excluded. Of 3396 
eligible patients (1764 (51.9%) children and 1632 (48.1%) adolescents), 1893 (55.7%) being 
male, 2017 (59.4%) were foreign-born and 1454 (42.8%) had pulmonary TB (PTB).  
Mycobacterial culture was performed in 2261 (66.6%) of the eligible patients with 1921 
(56.6%) being culture positive and 340 (10%) culture negative. Of 1921 patients with culture-
confirmed disease, 1610 (83.8%) had information on species. Of these, 1523 (94.6%) had M. 
tuberculosis and 87 (5.4%) had other M. tuberculosis complex. None of the patients were 
identified as nontuberculous mycobacterial infections. Most of the patients (2625 (77.3%)) 
were treated as presumed DS-TB, 591 (17.4%) as confirmed DS-TB and 180 (5.3%) as 
confirmed DR-TB (Table 2). Severe forms of TB (CNS or miliary TB) were notified in 100 
(2.9%) of 3396 eligible patients: 33 (33%) received BCG vaccination and 44 (44%) were 
BCG-unvaccinated. Of 44 severe cases who were BCG-unvaccinated, 23 (52.3%) were 
children <5 years, 15 (34.1%) were children aged 5-14 years and the remaining 6 (13.6%) 
were adolescents. 
By including both patients with known and unknown outcomes, overall success rates 
of 92.0% and 88.7% were shown in children and adolescents, respectively. Known outcomes 
were recorded in 3253 (95.8%) of 3396 eligible patients. Of these, success rates were shown 
in 95.9% children and 92.8% adolescents (Table 2). Annual success rates in children were 
constantly above 90% over the years from 1993-2018, and relatively higher compared to 
adolescents (Figure 1). LTFU was higher in adolescents (102 (6.5%)) than children (58 
(3.4%)). No treatment failure was reported and 22 (0.7%) of the total patients died during 
treatment (Table 2). Case fatality rates (CFR) for other sub-population are presented in 
Supplementary Table 2. 
 Our multivariate model showed that children aged 2-4 years had an increased odds of 
death compared to children aged 5-14 years (aOR: 10.42; 95% CI: 2.25-48.36). Positive 
associations with mortality were also shown in patients with central nervous system (CNS) 
TB (aOR: 5.14; 95% CI: 1.17-22.62), miliary TB (aOR: 10.25; 95% CI: 2.30-45.67), HIV 
coinfection (aOR: 8.60; 95% CI: 1.57-47.24), retreated TB cases (aOR: 10.12; 95% CI: 1.54-
66.47) and those who developed DILI during therapy (aOR: 6.50; 95% CI: 1.09-38.71). The 
ACF was associated with lower odds of death compared to PCF (aOR: 0.13; 95% CI: 0.03-
0.66) (Table 3). Patients with unknown history of TB contact, with unknown BCG status, who 
experienced TB symptoms or were hospitalised ≥1 week during treatment had a significant 
increased odds of death in univariate analysis but did not remain significant in multivariate 
analysis (Supplementary Table 3). Although unknown history of TB contact was not 
sustained in multivariate analysis as a predictor of mortality, it was significantly associated 
with higher odds of either patient’s delay (aOR: 2.36; 95% CI: 1.46-3.80) or doctor’s delay 
(aOR: 4.29; 95% CI: 2.48-7.42) compared to known TB contact history, adjusted for age, 
gender, smear microscopy and sites of TB. 
 Several factors were associated with higher odds of LTFU including adolescents 
(aOR: 1.91; 95% CI: 1.25-2.93), illegal immigrants (aOR: 4.28; 95% CI: 1.60-11.42), urban 
domicile (aOR: 1.59; 95% CI: 1.10-2.29), unknown history of TB contact (aOR: 1.99; 95% CI: 
1.19-3.34), confirmed DR-TB (aOR: 2.31; 95% CI: 1.05-5.10), single ADR (aOR: 2.12; 95% 
CI: 1.18-3.83), multiple ADRs (aOR: 7.84; 95% CI: 3.55-17.33) and treatment interruption 
>14 days (aOR: 6.93; 95% CI: 2.72-17.63). Treatment in recent years (aOR: 0.94; 95% CI: 
0.89-0.98) and treatment supervision by PHNs (aOR: 0.14; 95% CI: 0.07-0.29) were 
associated with lower odds of LTFU (Table 4). Being male and foreign-born were significantly 
associated with higher odds of LTFU in univariate analysis but not found statistically 
significant in multivariate analysis (Supplementary Table 4). However, our subgroup analysis 
identified that male foreign-born adolescents had a significantly increased odds of LTFU 
compared to female foreign-born adolescents (aOR: 2.31; 95% CI: 1.30-4.10), adjusted for 
year of diagnosis, area of living, DST results, presence of ADRs, treatment interruption >14 
days and treatment supervision by PHNs. 
The following factors were associated with higher odds of unfavourable outcome: 
children <5 years (aOR: 1.58; 95% CI: 1.02-2.46), adolescents (aOR: 1.56; 95% CI: 1.11-
2.19), illegal immigrants (aOR: 5.10; 95% CI: 2.15-12.10), unknown history of TB contact 
(aOR: 2.00; 95% CI: 1.30-3.07), miliary TB (aOR: 3.37; 95% CI: 1.42-8.03), multiple ADRs 
(aOR: 7.54; 95% CI: 3.56-15.99) and treatment interruption >14 days (aOR: 4.90; 95% CI: 
2.10-11.42). Treatment supervision by PHNs was associated with lower odds of 
unfavourable outcome (aOR: 0.08; 95% CI: 0.05-0.15) (Table 5). Results of the univariate 
analysis for unfavourable outcome are presented in Supplementary Table 5. 
DISCUSSION 
An overall high success rate of 92.0% in children was recorded in our study although this 
included children with unknown outcomes. This is relatively comparable with studies of 
children from other low-incidence countries such as Australia (89.4%) and the United 
Kingdom (UK) (88.0%) [19, 20]. A high success rate was also recorded in adolescents: 
comparable data from other low-incidence countries is lacking. This underlines that 
adolescents are often neglected in TB surveillance reports [3, 5]. The low mortality rate of 
<1% in our study is similar to those reported in the UK and Australia [19, 20] but is lower 
compared to various reports from high-incidence countries in Asia and Africa (3-17%) [11–
14]. Interestingly, a recent study from South Africa also reported less than 1% mortality rate 
in children; however, this number was probably higher as children with severe forms of TB 
admitted to hospital may have died before diagnosis or after diagnosis but prior to recording 
in the database [10]. 
Several risk factors of mortality are shown in our study including children aged 2-4 
years, CNS TB, miliary TB, HIV coinfection, retreated TB cases and cases with DILI. Overall, 
the increased risk of death in children under 5 years of age is consistent with those reported 
in a meta-analysis and a modelling study [6, 7]. However, in contrast to earlier findings from 
South Africa [10], our results did not confirm the risk of death in a subgroup of children <2 
years. In children <2-3 years, the progression of primary infection into severe disease (CNS 
or miliary TB) is more frequent [21]. These severe forms of disease were associated with 
mortality in our study, independently from age of the patients. In high-incidence countries, 
BCG vaccination has been reported as a highly cost-effective intervention to prevent CNS TB 
and miliary TB [22]. In The Netherlands, BCG vaccination is only targeted to new-borns with 
a parent coming from a country with estimated TB incidence >50 per 100,000 population, 
and offered for immigrants <12 years with no evidence of BCG vaccination at pre-entry TB 
screening [23]. Notably, more patients with severe disease in our study were BCG-
unvaccinated: half of them were <5 years of age. These results support the previous 
recommendation by Erkens et al to improve the coverage of BCG vaccination among eligible 
risk groups in The Netherlands [24]. 
The role of TB/HIV coinfection as a predictor of mortality in children is supported by 
various studies mostly from HIV-endemic settings [10–13]. For TB/HIV co-infected children 
taking antiretroviral therapy (ART), the risk of death is lower than children without ART [6]. In 
our cohorts, ART status was not completely clear because it was being recorded in the NTR 
only since 2016. Next, a recurrent episode of TB can be due to endogenous reactivation of 
indolent mycobacteria (relapse) or exogenous reinfection, and the latter can be caused by 
MDR M. tuberculosis strains [25]. Two patients with recurrent TB who died in our study were 
classified as non-relapse patients, one of which was treated for MDR-TB. It is possible that 
MDR-TB also plays a role in increasing the risk of mortality in recurrent TB.  
DILI is one of the most frequent and serious ADRs during TB-therapy [26], and also 
reported as a predictor of prolonged TB treatment in a Dutch setting [27]. Although with a 
relatively lower rate of DILI in our study (1.8%) compared to other studies of children in 
Japan (8.1%) and Indonesia (15%) [28, 29], its clinical implication in increasing the risk of 
mortality should be taken seriously. Two studies from India and the UK also reported DILI as 
a contributing cause of death in adult TB patients [30, 31], with the risk of mortality being 
even higher if accompanied by jaundice, ascites or encephalopathy [31]. Based on the 
current WHO guidelines for children, regular monitoring of liver function tests (LFTs) during 
TB-therapy is not mandatory and only recommended if liver tenderness, hepatomegaly, 
jaundice or early onset of vomiting occur during treatment [32]. Given that severe 
hepatotoxicity can develop in patients with asymptomatic DILI [33], regular monitoring of 
LFTs as suggested for adults undergoing TB therapy might also benefit children to improve 
treatment outcomes and to prevent mortality.  
In The Netherlands, pre-entry LTBI screening is carried out for every immigrant and 
asylum seeker <18 years, and radiographic screening is recently suggested only in children 
between 12-17 years from a country with TB incidence ≥100 per 100,000 population [34]. 
The ACF interventions such as screening for immigrants and asylum seekers as well as 
source and contact investigations have proven useful in our study to prevent mortality 
compared to PCF. Given that unknown history of TB contact was also found as a risk factor 
of either patient’s or doctor’s delay, this highlights the benefits of advocating ACF for early 
diagnosis and early treatment (including preventive therapy), in order to prevent deterioration 
of the disease. A large randomised controlled trial (RCT) from Vietnam supports that ACF is 
a cost-effective intervention to increase TB case detection and to reduce all-cause mortality 
[35, 36]. A modelling study also reported that household contact investigations could 
substantially prevent both TB cases and mortality in children [37]. 
For LTFU, our study identifies the following risk factors: adolescent age, illegal 
immigrants, unknown history of TB contact, urban domicile, confirmed DR-TB, presence of 
ADRs and treatment interruption >14 days. The increased risk of LTFU in adolescents 
particularly in male foreign-born adolescents might be due to the lack of awareness of the 
special needs of this population [15]. To improve adherence in adolescents, appropriate 
interventions should be understood by considering their developmental and psychosocial 
issues, tailoring the treatment regimen and ensuring peer and family supports [38]. 
Implementation of DOT in our study was not statistically significant to prevent LTFU even in a 
particular subgroup of adolescents. This is supported by a meta-analysis that poor 
adherence in TB treatment cannot be resolved by DOT intervention [39]. A recently 
published RCT from the UK reported that smartphone-enabled video-observed therapy 
(VOT) is more effective, preferable and cheaper than DOT for TB treatment observation [40]. 
In The Netherlands where internet connectivity is not an issue, VOT might also be relevant 
as an alternative to DOT, particularly for adolescents who have a high mobile-internet 
engagement. A new framework of digital health (e-health) as currently recommended by the 
WHO [41], might also benefit to ensure treatment adherence. Even though this e-health 
system has not been widely used in The Netherlands [23], it has great potential as a more 
patient-friendly intervention for therapy monitoring, particularly for high-risk groups and other 
individuals with complex confounders (e.g. patients living in urban areas or treated for DR-
TB).  
Since 2005, a central web-based TB surveillance system was introduced and 
laboratory data were matched with the NTR in real-time. These improvements might have 
contributed to the reduced number of LTFU cases in recent years. This is supported by our 
results that most of the LTFU cases (79%) were notified before 2005. The improved TB 
outcomes might also be related to the large number of stakeholders involved in TB control 
activities; from the MPHS, KNCV, RIVM, and other health professionals such as pulmonary 
physicians, paediatricians, TB control physicians, medical microbiologists, medical 
technicians and PHNs [23].  Our study confirms that treatment supervision by PHNs is a 
protective factor of LTFU as well as unfavourable outcome.  
A particular strength of this study is a relatively wide range of variables included in the 
analysis from demographics to disease notification-, clinical-, bacteriological- and treatment-
related factors. However, our study has several limitations that should be acknowledged. 
Due to the retrospective nature of the study using routine data, patient records were partly 
incomplete for some of the variables. Even though notification of TB is mandatory, the 
possibility of undernotification cases cannot be ruled out. Through a capture-recapture 
analysis, the adjusted undernotification of TB in 1998 was estimated to be 7.3% [42]. 
However, the completeness of notification is expected to have increased since 2005 when 
improvements were made to the NTR. The high proportion of patients with presumed DS-TB 
in our cohorts can be explained by these changes, given that 1139 (99%) of 1150 patients 
with culture-confirmed disease but did not have information on DST results were registered 
before 2005. Next, our database cannot distinguish between TB contact history with an 
infectious DR-TB and DS-TB case, and this may have led to misclassification of presumed 
DS-TB in some patients who should have been classified as presumed DR-TB. The low 
proportion of patients who died and were LTFU in our cohorts could also limit the statistical 
power of the study. Although the definition of mortality used in this study has followed the 
current WHO guidelines as all-cause mortality before starting or during the course of 
treatment [32], the differentiation of death due to TB from other causes along with post-
mortem evidence could provide a more accurate characterisation of TB-related mortality. In 
addition, given the details on LFTs and clinical features of DILI are not registered in the NTR, 
further classification of symptomatic versus asymptomatic DILI cannot be presented. 
In conclusion, this study demonstrates a high rate of successful treatment outcome in 
children and adolescents treated for TB in The Netherlands from 1993-2018. Specific risk 
groups for mortality, LTFU and unfavourable outcome have been identified for further 
development of early interventions to support these patients once diagnosed with TB. 
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Table 1. Treatment outcome definitions used in this study 
 
Outcomes  Definition for DS-TB Definition for DR-TB 
Cured A patient who had completed a full course of therapy or at least 80% of 
the prescribed doses with a confirmed culture-negative at the end of 
treatment. 
A patients who had treatment completed without evidence of 
failure with three or more consecutive negative cultures taken at least 
30 days apart after the intensive phase 
Treatment completed A patient who had taken all of the prescribed doses or at least 80% of 
them without any information of sputum culture at the end of treatment. 
A patients who had treatment completed without evidence of failure, but 
no record that three or more consecutive cultures taken at least 30 
days apart were negative after the intensive phase 
Died A patient who died for any reason before starting or during the course 
of treatment. 
A patient who died for any reason during the course of treatment 
Treatment failed A patient whose sputum culture was positive after 5 months or later 
during treatment. 
A patient who met one of the following criteria: 1) lack of conversion by 
the end of the intensive phase, 2) bacteriological reversion in the 
continuation phase after conversion to negative, 3) evidence of 
additional acquired resistance to fluoroquinolone or second-line 
injectable drugs, and 4) of adverse drug reactions requiring 
discontinuation of treatment.  
Lost to follow-up A patient who met one of the following criteria: treatment interruption for 
two consecutive months or more; treatment completion of less than 
80% of the prescribed doses; treatment incompletion of 6 months within 
the 9-month treatment period; or treatment incompletion of 9 months 
within the 12-month treatment period. 
A patient whose treatment was interrupted for 2 consecutive months or 
more. 
Not evaluated (Unknown)  A patient for whom no treatment outcome (cured, treatment completed, 
died, treatment failed, and lost to follow-up) was assigned in the 
database. This included cases “transferred out” to another unit 
(country) with unknown treatment results. 
A patient for whom no treatment outcome was assigned in the 
database. This included cases “transferred out” to another unit 
(country) with unknown treatment results 
Treatment success The sum of “cured” and “treatment completed”. The sum of “cured” and “treatment completed”. 
 
DR-TB, drug-resistant tuberculosis; DS-TB, drug-susceptible tuberculosis. 
DR-TB comprised of mono-resistant TB (resistance to one first-line anti-TB drug only); poly-resistant TB (resistance to more than one first-line anti-TB drug other than isoniazid 
and/or rifampicin); multidrug-resistant TB (MDR-TB) (resistance to at least both isoniazid and rifampicin); extensively drug-resistant TB (resistance to any fluoroquinolone and to 
at least one of three second-line injectable drugs (capreomycin, kanamycin and amikacin) in addition to MDR-TB); and rifampicin resistant TB (resistance to rifampicin with or 
without resistance to other anti-TB drugs). Source: [16, 18]. 
 
  
Table 2. Characteristics of children and adolescents treated for TB in The Netherlands 
 
Characteristics Total cases 
(n=3396) 
 <5 years 
(n=638) 
 5-14 years 
(n=1126) 
 15-18 years 
(n=1632) 
Year of diagnosis     
 1993-1998 1092 (32.2) 218 (34.2) 400 (35.5) 474 (29.0) 
 1999-2003 1005 (29.6) 173 (27.1) 270 (24.0) 562 (34.4) 
 2004-2008 485 (14.3) 110 (17.2) 177 (15.7) 198 (12.1) 
 2009-2013 398 (11.7) 79 (12.4) 151 (13.4) 168 (10.3) 
 2014-2018 416 (12.2) 58 (9.1) 128 (11.4) 230 (14.1) 
Gender     
 Male 1893 (55.7) 337 (52.8) 525 (46.6) 1031 (63.2) 
 Female 1503 (44.3) 301 (47.2) 601 (53.4) 601 (36.8) 
Born in The Netherlands     
 Yes 1350 (39.8) 502 (78.7) 522 (46.4) 326 (20.0) 
 No 2017 (59.4) 130 (20.4) 594 (52.8) 1293 (79.2) 
 Unknown 29 (0.9) 6 (0.9) 10 (0.9) 13 (0.8) 
Site of TB     
 PTB 1454 (42.8) 229 (35.9) 401 (35.6) 824 (50.5) 
 EPTB 1570 (46.2) 352 (55.2) 600 (53.3) 618 (37.9) 
 PTB + EPTB 372 (11.0) 57 (8.9) 125 (11.1) 190 (11.6) 
Reason for TB investigation     
 Presentation of TB symptoms 1582 (46.6) 178 (27.9) 478 (42.5) 926 (56.7) 
 Contact investigation 944 (27.8) 343 (53.8) 429 (38.1) 172 (10.5) 
 Screening high-risk groups 620 (18.3) 61 (9.6) 162 (14.4) 397 (24.3) 
 Others 35 (1.0) 12 (1.9) 11 (1.0) 12 (0.7) 
 Unknown 215 (6.3) 44 (6.9) 46 (4.1) 125 (7.7) 
AFB smear microscopy (sputum or BAL)     
 Negative 570 (16.8) 51 (8.0) 158 (14.0) 361 (22.1) 
  Non-cavitary TB 515 (15.2) 48 (7.5) 147 (13.0) 320 (19.6) 
  Cavitary TB 25 (0.7) 1 (0.1) 4 (0.3) 20 (1.2) 
 Positive 534 (15.7) 26 (4.1) 121 (10.7) 387 (23.7) 
  Non-cavitary TB 324 (9.5) 23 (3.6) 73 (6.5) 228 (14.0) 
  Cavitary TB 187 (5.5) 2 (0.3) 43 (3.8) 142 (8.7) 
 Unknown/ not done 2292 (67.5) 561 (87.9) 847 (75.2) 884 (54.2) 
Mycobacterial culture     
 Negative 340 (10.0) 60 (9.4) 130 (11.5) 150 (9.2) 
 Positive 1921 (56.6) 195 (30.6) 506 (44.9) 1220 (74.8) 
 Unknown/ not done 1135 (33.4) 383 (60.0) 490 (43.5) 262 (16.1) 
Drug-susceptibility testing      
 Confirmed DS-TB 591 (17.4) 46 (7.2) 144 (12.8) 401 (24.6) 
 Presumed DS-TB 2625 (77.3) 568 (89.0) 936 (83.1) 1121 (68.7) 
  Culture positive, DST unknown 1150 (33.9) 125 (19.6) 316 (28.1) 709 (43.4) 
  Culture negative or unknown 1475 (43.4) 443 (69.4) 620 (55.1) 412 (25.2) 
 Confirmed DR-TB 180 (5.3) 24 (3.8) 46 (4.1) 110 (6.7) 
  Mono/poly H 131 (3.9) 20 (3.1) 33 (2.9) 78 (4.8) 
   Mono/poly R 2 (0.1) 0 (0.0) 0 (0.0) 2 (0.1) 
  Mono Z 14 (0.4) 3 (0.5) 4 (0.4) 7 (0.4) 
  MDR-TB 32 (0.9) 1 (0.2) 9 (0.8) 22 (1.3) 
  XDR-TB 1 (0.0) 0 (0.0) 0 (0.0) 1 (0.1) 
Treatment outcomes (uncorrected)     
 Cured/completed 3071 (90.4) 577 (90.4) 1046 (92.9) 1448 (88.7) 
 Lost to follow-up 160 (4.7) 24 (3.8) 34 (3.0) 102 (6.3) 
 Failed 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 Died 22 (0.6) 9 (1.4) 3 (0.3) 10 (0.6) 
 Not evaluated (unknown) 143 (4.2) 28 (4.4) 43 (3.9) 72 (4.4) 
Treatment outcomes (corrected)
* 
    
 Total, n 3253 610 1083 1560 
 Cured/completed 3071 (94.4) 577 (94.6) 1046 (96.6) 1448 (92.8) 
 Lost to follow-up 160 (4.9) 24 (3.9) 34 (3.1) 102 (6.5) 
 Failed 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 Died 22 (0.7) 9 (1.5) 3 (0.3) 10 (0.6) 
 
Data are presented as number  with percentages (%); AFB, acid-fast bacilli ; BAL, bronchoalveolar lavage; DST, drug-
susceptibility testing; DSTB, drug-susceptible tuberculosis; DRTB, drug-resistant tuberculosis; EPTB, extra-pulmonary 
tuberculosis; H, isoniazid; HIV, human immunodeficiency virus; MDR-TB, multidrug-resistant tuberculosis; PTB, pulmonary 
tuberculosis; R, rifampicin; XDR-TB, extensively drug-resistant tuberculosis; Z, pyrazinamide. 
*Excluded patients with unknown outcomes. 
 
Table 3. Final model for factors associated with mortality in children and adolescents treated for TB in the Netherlands 
 
 Died (n=22) Alive
α
 (n=3071) cOR (95% CI) P-value aOR (95% CI) P-value 
Age       
 <2 years 2 (9.1) 220 (7.2) 3.17 (0.53-19.08) 0.208 1.22 (0.16-9.56) 0.846 
 2-4 years 7 (31.8) 357 (11.6) 6.84 (1.76-26.58) 0.006 10.42 (2.25-48.36) 0.003 
 5-14 years 3 (13.6) 1046 (34.1) 1.00 - 1.00 - 
 15-18 years 10 (45.5) 1448 (47.2) 2.41 (0.66-8.77) 0.183 1.13 (0.27-4.77) 0.863 
Type of case-finding       
 Passive 15 (68.2) 1478 (48.1) 1.00 - 1.00 - 
 Active 2 (9.1) 1511 (49.2) 0.13 (0.03-0.57) 0.007 0.13 (0.03-0.66) 0.014 
 Unknown 5 (22.7) 82 (2.7) 6.01 (2.13-16.93) 0.001 5.41 (1.36-21.44) 0.016 
Main localisation of TB       
 Lungs 8 (36.4) 1302 (42.4) 1.00 - 1.00 - 
 CNS 4 (18.2) 49 (1.6) 13.29 (3.87-45.62) <0.001 5.14 (1.17-22.62) 0.030 
 Miliary  6 (27.3) 35 (1.1) 27.90 (9.19-84.70) <0.001 10.25 (2.30-45.67) 0.002 
 Others 0 (0.0) 1556 (50.7) n/a 0.987 n/a 0.986 
 Unknown 4 (18.2) 129 (4.2) 5.05 (1.50-16.99) 0.009 3.51 (0.89-3.89) 0.074 
HIV status       
 No/unknown 18 (81.8) 3039 (99.0) 1.00 - 1.00 - 
 HIV positive 4 (18.2) 32 (1.0) 21.10 (6.76-65.86) <0.001 8.60 (1.57-47.24) 0.013 
Previously treated for TB       
 No 13 (59.1) 2796 (91.0) 1.00 - 1.00 - 
 Yes 2 (9.1) 60 (2.0) 7.17 (1.58-32.47) 0.011 10.12 (1.54-66.47) 0.016 
 Unknown 7 (31.8) 215 (7.0) 7.00 (2.76-17.73) <0.001 7.89 (2.31-26.92) 0.001 
Type of ADR       
 No/unknown 19 (86.4) 2900 (94.4) 1.00 - 1.00 - 
 DILI 2 (9.1) 54 (1.8) 5.65 (1.28-24.87) 0.022 6.50 (1.09-38.71) 0.040 
 Others  1 (4.5) 117 (3.8) 1.30 (0.17-9.83) 0.796 0.99 (0.11-8.81) 0.992 
 
Hosmer-Lemeshow test, P=0.976; area under the ROC curve, 0.96 (95% CI, 0.94-0.99). 
Data are presented as number  with percentages (%); ADR, adverse drug reaction; aOR, adjusted odds ratio; CI, 
confidence interval; CNS, central nervous system; cOR, crude odds ratio; DILI, drug-induced liver injury; HIV, 
human immunodeficiency virus; n/a, not applicable; ROC, receiver operating characteristic. 
α
Included patients who achieved cure or completed treatment and excluded those who were LTFU or with 
unknown outcomes. 
  









cOR (95% CI) P-value aOR (95% CI) P-value 
Year of diagnosis
#




0.94 (0.92-0.97) <0.001 0.94 (0.89-0.98) 0.011 
Age       
 <5 years 24 (15.0) 577 (18.8) 1.28 (0.75-2.18) 0.364 1.47 (0.84-2.59) 0.178 
 5-14 years 34 (21.3) 1046 (34.1) 1.00 - 1.00 - 
 15-18 years 102 (63.7) 1448 (47.2) 2.17 (1.46-3.22) <0.001 1.91 (1.25-2.93) 0.003 
Immigrants or asylum seekers       
 No 51 (31.9) 1261 (41.1) 1.00 - 1.00 - 
 Yes, duration <2.5 y 71 (44.4) 1139 (37.1) 1.54 (1.07-2.23) 0.021 1.15 (0.73-1.81) 0.549 
 Yes, illegal immigrants 8 (5.0) 22 (0.7) 8.99 (3.82-21.17) <0.001 4.28 (1.60-11.42) 0.004 
 Yes, duration >2.5 y 17 (10.6) 502 (16.3) 0.84 (0.48-1.46) 0.533 0.59 (0.32-1.10) 0.099 
 Yes, duration unknown 13 (8.1) 147 (4.8) 2.19 (1.16-4.12) 0.015 1.32 (0.65-2.66) 0.443 
Area of living       
 Urban
a
 59 (36.9) 854 (27.8) 1.52 (1.09-2.11) 0.014 1.59 (1.10-2.29) 0.014 
 Suburban
b
 101 (63.1) 2217 (72.2) 1.00 - 1.00 - 
Known history of TB contact       
 No 135 (84.4) 2090 (68.1) 2.53 (1.64-3.91) <0.001 1.99 (1.19-3.34) 0.009 
 Yes 25 (15.6) 981 (31.9) 1.00 - 1.00 - 
Drug susceptibility       
 Confirmed DS-TB 16 (10.0) 552 (18.0) 1.00 - 1.00 - 
 Presumed DS-TB 127 (79.4) 2365 (77.0) 1.85 (1.09-3.14) 0.022 1.38 (0.72-2.64) 0.332 
 Confirmed DR-TB 17 (10.6) 154 (5.0) 3.81 (1.88-7.71) <0.001 2.31 (1.05-5.10) 0.038 
Presence of ADR       
 No/unknown 130 (81.3) 2900 (94.4) 1.00 - 1.00 - 
 Yes, single ADR 19 (11.9) 147 (4.8) 2.88 (1.73-4.80) <0.001 2.12 (1.18-3.83) 0.012 
 Yes, multiple ADRs 11 (6.9) 24 (0.8) 10.22 (4.90-21.32) <0.001 7.84 (3.55-17.33) <0.001 
Treatment interruption >14 days       
 No 20 (12.5) 1045 (34.0) 1.00 - 1.00 - 
 Yes 10 (6.3) 42 (1.4) 12.44 (5.48-28.23) <0.001 6.93 (2.72-17.63) <0.001 
 Unknown  130 (81.3) 1984 (64.6) 3.42 (2.13-5.51) <0.001 1.03 (0.45-2.35) 0.938 
Supervision by PHNs       
 No 12 (7.5) 34 (1.1) 1.00 - 1.00 - 
 Yes 141 (88.1) 2976 (96.9) 0.13 (0.07-0.26) <0.001 0.14 (0.07-0.29) <0.001 
 Unknown 7 (4.4) 61 (2.0) 0.32 (0.12-0.90) 0.031 0.21 (0.07-0.64) 0.006 
 
Hosmer-Lemeshow test, P=0.745; area under the ROC curve, 0.75 (95% CI, 0.72-0.79).  
Data are presented as number with percentages (%), unless stated otherwise: 
#
median with interquartile ranges 
(IQR); ADR, adverse drug reactions; aOR, adjusted odds ratio; CI, confidence interval; cOR, crude odds ratio; 
DS-TB, drug-susceptible tuberculosis; DR-TB, drug resistant tuberculosis; LTFU, lost to follow-up; PHNs, public 
health nurses; ROV, receiver operating characteristics; ROC, receiver operating characteristic. 
£
Included patients who achieved cure or completed treatment and excluded those who died or with unknown 
outcomes. 
a
The Hague, Utrecht (stad), Amsterdam and Rotterdam; 
b
Groningen, Friesland, Zeeland, Drenthe, Overijssel, 
Gelderland, Zuid-Holland, Limburg, Utrecht, Noord-Holland, Noord-Brabant, Flevoland or other areas 
 
  
Table 5. Final model for factors associated with unfavourable outcome in children and adolescents treated for TB 










cOR (95% CI) P-value aOR (95% CI) P-value 
Age       
 <5 years 61 (16.8) 577 (18.8) 1.38 (0.98-1.96) 0.069 1.58 (1.02-2.46) 0.040 
 5-14 years 80 (24.6) 1046 (34.1) 1.00 - 1.00 - 
 15-18 years 184 (56.6) 1448 (47.2) 1.66 (1.26-2.19) <0.001 1.56 (1.11-2.19) 0.010 
Immigrants or asylum seekers       
 No 98 (30.2) 1261 (41.1) 1.00 - 1.00 - 
 Yes, duration <2.5 y 134 (41.2) 1139 (37.1) 1.51 (1.15-1.99) 0.003 1.09 (0.74-1.59) 0.663 
 Yes, illegal immigrants 17 (5.2) 22 (0.7) 9.94 (5.11-19.34) <0.001 5.10 (2.15-12.10) <0.001 
 Yes, duration >2.5 y 37 (11.4) 502 (16.3) 0.95 (0.64-1.40) 0.791 0.74 (0.45-1.20) 0.222 
 Yes, duration unknown 39 (12.0) 147 (4.8) 3.41 (2.27-5.14) <0.001 1.71 (0.99-2.96) 0.054 
Known TB contact history       
 No 274 (84.3) 2090 (68.1) 2.52 (1.85-3.43) <0.001 2.00 (1.30-3.07) 0.002 
 Yes 51 (15.7) 981 (31.9) 1.00 - 1.00 - 
Main localisation of TB       
 Primary TB infection 30 (9.2) 673 (21.9) 0.54 (0.36-0.82) 0.004 0.85 (0.52-1.41) 0.534 
 Lungs 107 (32.9) 1302 (42.4) 1.00 - 1.00 - 
 Respiratory tract 18 (5.5) 388 (12.6) 0.56 (0.34-0.94) 0.029 0.67 (0.39-1.15) 0.146 
 CNS 7 (2.2) 49 (1.6) 1.74 (0.77-3.93) 0.184 1.52 (0.60-3.87) 0.382 
 Abdominal 6 (1.8) 51 (1.7) 1.43 (0.60-3.41) 0.418 1.81 (0.72-4.53) 0.207 
 Osteoarticular 6 (1.8) 67 (2.2) 1.09 (0.46-2.57) 0.844 1.25 (0.51-3.05) 0.629 
 Other organs 33 (10.2) 377 (12.3) 1.06 (0.71-1.60) 0.761 0.83 (0.53-1.31) 0.427 
 Miliary  9 (2.8) 35 (1.1) 3.13 (1.46-6.68) 0.003 3.37 (1.42-8.03) 0.006 
 Unknown 109 (33.5) 129 (4.2) 10.28 (7.45-14.19) <0.001 3.99 (2.56-6.20) <0.001 
Previously treated for TB       
 No 273 (84.0) 2796 (91.0) 1.00 - 1.00 - 
 Yes 13 (4.0) 60 (2.0) 2.22 (1.20-4.09) 0.011 2.04 (0.98-4.24) 0.057 
 Unknown 39 (12.0) 215 (7.0) 1.86 (1.29-2.67) 0.001 1.07 (0.67-1.71) 0.765 
Presence of ADR       
 No/unknown 291 (89.5) 2900 (94.4) 1.00 - 1.00 - 
 Yes, single ADR 20 (6.2) 147 (4.8) 1.36 (0.84-2.20) 0.216 1.57 (0.89-2.77) 0.120 
 Yes, multiple ADRs 14 (4.3) 24 (0.8) 5.81 (2.97-11.36) <0.001 7.54 (3.56-15.99) <0.001 
Treatment interruption >14 days       
 No 42 (12.9) 1045 (34.0) 1.00 - 1.00 - 
 Yes 11 (3.4) 42 (1.4) 6.52 (3.13-13.55) <0.001 4.90 (2.10-11.42) <0.001 
 Unknown  272 (83.7) 1984 (64.6) 3.41 (2.44-4.76) <0.001 1.58 (1.09-2.92) 0.016 
Hospitalised ≥1 week       
 No/ <1 week 238 (73.2) 2153 (70.1) 1.00 - 1.00 - 
 Yes 68 (20.9) 815 (26.5) 0.75 (0.57-1.00) 0.050 0.71 (0.51-1.01) 0.055 
 Unknown 19 (5.8) 103 (3.4) 1.67 (1.01-2.77) 0.048 0.86 (0.46-1.60) 0.633 
Supervised by PHNs       
 No 32 (9.8) 34 (1.1) 1.00 - 1.00 - 
 Yes 192 (59.1) 2976 (96.9) 0.07 (0.04-0.11) <0.001 0.08 (0.05-0.15) <0.001 
 Unknown 101 (31.1) 61 (2.0) 1.76 (0.99-3.14) 0.055 1.01 (0.51-2.00) 0.997 
 
Hosmer-Lemeshow test, P=0.506; area under the ROC curve, 0.81 (95% CI, 0.78-0.84). 
Data are presented as number (n) with percentages, unless stated otherwise: 
#
median with interquartile ranges 
(IQR); ADR, adverse drug reactions; aOR, adjusted odds ratio; CI, confidence interval; CNS, central nervous 
system; cOR, crude odds ratio; HIV, human immunodeficiency virus; PHNs, public health nurses; ROC, receiver 
operating characteristic. 
β
The sum of patients who achieved cure or completed treatment. 
¥





Figure 1. Notified TB cases and trend of success rates among children and adolescents 





Supplementary table 1. Operational definitions of the explanatory variables 
 
Variable Definition 
Demographic characteristics  
 Children Patients aged <15 years 
 Adolescents Patients aged 15-18 years 
 WHO Region Six regions classified by the World Health Organisation (WHO) including African 
Region, Region of the Americas, South-East Asia Region, European region, 
Eastern Mediterranean Region, Western Pacific Region 
 Immigrant A person who was born outside The Netherlands with a legal residence status 
other than tourist or refugee.  
 Non-immigrant A native Dutch (born in The Netherlands and both parents born in The 
Netherlands) or a second generation immigrant (born in The Netherlands and 
have at least one foreign-born parent). 
 Asylum seeker A person who has left their home country as a political refugee and is seeking 
asylum elsewhere. 
 Urban  Four biggest cities of the Netherlands (The Randstad) including The Hague, 
Utrecht, Amsterdam and Rotterdam. 
 Suburban The province of Groningen, Friesland, Zeeland, Drenthe, Overijssel, Gelderland, 
Zuid-Holland, Limburg, Utrecht, Noord-Holland, Noord-Brabant, Flevoland or 
other areas. 
TB notification and clinical characteristics 
 Active case-finding (ACF) The systematic screening for active TB cases in a predetermined high-risk group 
for TB. This included screening for immigrants and refugees, screening for 
detainees, hospital staff screening, screening for travellers after their journey 
from TB endemic areas, screening for patients diagnosed with HIV positive, TB-
contact investigation, screening for homeless and drug addicts, periodic 
screening for health care worker or person working with TB risk groups, 
screening prior to immunosuppressive treatment, X-ray examination for patients 
with LTBI, and others (screening as a baseline measurement prior to BCG/ 
travel/ appointment investigation). 
 Passive case-finding (PCF) A patient who had experienced TB symptoms (complaints) and came to the 
healthcare system by their own accord. 
 Known history of TB contact A patient who had close contact history with an infectious TB case. 
 Travel history in TB endemic 
area >3 month 
A patient who had travelled in a country with TB incidence >100 per 100,000 
population for more than three months within the past two years. 
 Pulmonary TB (PTB) All forms of TB in the lungs, isolated tracheal or bronchus TB, laryngeal TB, and 
other specified respiratory TB. 
 Extrapulmonary TB (EPTB) TB within other locations in the body than the lungs, which may have included 
isolated EPTB or a combination of PTB and EPTB. 
 Cavitary TB Cavitary TB involves the upper lobes of the lung and characterised by the 
presence of cavities in the lung tissue or enlarged air spaces. 
 BCG-vaccinated patient A patient who had a documented medical information of vaccination history or 
with the presence of a Bacillus Calmette Guerin (BCG) scar 
 Had TB symptoms A patient who had symptoms of TB disease prior to treatment. Since 2005, only 
“cough complaint” was recorded in the database as TB symptoms (applicable 
only for patients with PTB or PTB+EPTB) 
 Patient’s delay The number of weeks (at least 1 week) from the onset of TB symptoms and the 
date of the first contact with health care related to this episode. 
  
 
 Doctor’s delay The number of weeks (at least 1 week) between the first contact with health care 
for TB episode and the start of TB treatment. 
 Comorbidity Comorbidity group was composed by including patients with human 
immunodeficiency virus (HIV), malignancy, and other diseases (diabetes 
mellitus, renal insufficiency/ dialysis or organ transplantation). 
Bacteriological characteristics  
 Smear positive The specimen from sputum, bronchoalveolar lavage (BAL) or other body 
materials noted as at least +1 for acid-fast bacilli (AFB+) on microscopy using 
Ziehl-Neelsen stain. 
 Species of Mycobacterium Species of Mycobacterium consists of M. tuberculosis, M. bovis, and other M. 
tuberculosis complex such as M. africanum, M. microti, M. canetti or unspecified 
M. tuberculosis complex 
 Confirmed DS-TB A patient with a susceptible result of drug-susceptibility testing (DST) for all first-
line anti-TB drugs (isoniazid, rifampicin, pyrazinamide and ethambutol). 
 Presumed DS-TB A patient treated with first-line anti-TB drugs without sufficient information on 
DST results 
 Confirmed DR-TB A patient with DST results of being resistant to at least one of the fist-line TB 
drugs. Confirmed DR-TB was categorised as mono-resistant, poly-resistance, 
multidrug-resistant (MDR), or extensively drug-resistant (XDR) TB. 
Treatment characteristics  
 Retreated patient A patient who had previously started TB treatment but was discontinued after 1 
month or more. It included a patient with treatment after relapse, treatment after 
failure, treatment after loss to follow-up, and other previously treated cases. 
 Intermittent dosing Anti TB-drugs dosing less than once daily during the entire course of treatment 
or part of the treatment. 
 Adverse drug reactions 
(ADRs) 
Unwanted and undesirable effects of a medication defined by the treating 
physician, and demanding an interruption or change of the treatment regimen. 
ADRs included antituberculosis drug-induced liver injury (DILI), neurological 
disorders, mental disorders, vision disorders, drug allergy, arthralgia, and others. 
Any combination of ≥2 ADRs were classified as multiple ADRs. 
 Drug-induced liver injury 
(DILI) 
DILI due to anti-TB drugs was defined as an increased levels of alanine 
aminotransferase >3x the upper limit of normal (ULN) in the presence of 
symptoms of hepatotoxicity or >5x the ULN in the absence of symptoms. 
 Treatment interruption >14 
days 
A patient who had interrupted treatment to more than 14 days but less than 2 
months, either caused by adverse effects or other reasons. 
 Treatment supervision by 
public health nurses (PHNs) 
Supportive discussions with patients and their family to provide TB education as 
well as identification of obstacles that influence treatment adherence. The 
intensity of supervision varies from daily to monthly contacts. 
 Directly observed therapy 
(DOT) 
Every dose of anti-TB drugs taken under direct observation for a period of time, 
provided by either PHNs or other selected third parties such as family members 
or home nursing services 
 
Source: [1,2]  
  
 
Supplementary table 2. Estimated case-fatality rates stratified by specific sub-population in children 




Total, n Deaths, n CFR (95% CI) 
Total patients  3093 22 0.7 (0.4-1.1) 
Stratified by age    
 0-4 years 586 9 1.5 (0.7-2.9) 
 5-14 years 1049 3 0.3 (0.1-0.8) 
 15-18 years 1458 10 0.7 (0.3-1.3) 
Stratified by DST    
 Confirmed DS-TB 558 6 1.1 (0.4-2.3) 
 Presumed DS-TB 2379 14 0.6 (0.3-1.0) 
 Confirmed DR-TB 156 2 1.3 (0.2-4.6) 
Stratified by HIV(+) and age    
 HIV(+) aged 0-4 years 4 1 25.0 (0.6-80.6) 
 HIV(+) aged 5-14 years 10 0 0.0 (0.0-33.6) 
 HIV(+) aged 15-18 years 23 3 13.0 (2.8-33.6) 
Stratified by TB localisation    
 Lungs 1310 8 0.6 (0.3-1.2) 
 CNS 53 4 7.5 (2.1-18.2) 
 Miliary 41 6 14.6 (5.6-29.2) 
Stratified by BCG vaccination and age    
 BCG-unvaccinated, aged 0-4 years 405 3 0.7 (0.2-2.1) 
 BCG-unvaccinated, aged 5-14 years 468 1 0.2 (0.0-1.2) 
 BCG-unvaccinated, aged 15-18 years 299 1 0.3 (0.0-1.8) 
 
Abbreviations: BCG, Bacillus Calmette-Guerin; CFR, case fatality rate; CI, confidence interval; CNS, central 
nervous system; DST, drug-susceptibility testing; DS-TB, drug-susceptible tuberculosis; DR-TB, drug-resistant 
tuberculosis; HIV, human immunodeficiency virus. 
α







Supplementary table 3. Factors associated with mortality in children and adolescents treated for TB in 
the Netherlands using univariate logistic regression analysis 
 






OR (95% CI) P-value 
Demographic characteristics     
Year of diagnosis
#




0.95 (0.89-1.01) 0.117 
Year of diagnosis     
 1993-1998 9 (40.9) 967 (31.5) 1.00  
 1999-2003 7 (31.8) 877 (28.6) 0.86 (0.32-2.31) 0.761 
 2004-2008 4 (18.2) 456 (14.8) 0.94 (0.29-3.08) 0.922 
 2009-2013 2 (9.1) 371 (12.1) 0.58 (0.12-2.69) 0.486 
 2014-2018 0 (0.0) 400 (13.0) n/a 0.993 
a
Age      
 <2 years 2 (9.1) 220 (7.2) 3.17 (0.53-19.08) 0.208 
 2-4 years 7 (31.8) 357 (11.6) 6.84 (1.76-26.58) 0.006 
 5-14 years 3 (13.6) 1046 (34.1) 1.00 - 
 15-18 years 10 (45.5) 1448 (47.2) 2.41 (0.66-8.77) 0.183 
Gender     
 Male 12 (54.5) 1690 (55.0) 0.98 (0.42-2.28) 0.981 
 Female 10 (45.5) 1381 (45.0) 1.00  
Born in The Netherlands     
 Yes 7 (31.8) 1252 (40.8) 1.00  
 No 15 (68.2) 1795 (58.5) 1.49 (0.61-3.68) 0.381 
 Unknown 0 (0.0) 24 (0.8) n/a 0.998 
WHO Region of birth      
 European 8 (36.4) 1362 (44.4) 1.00  
 African 7 (31.8) 565 (18.4) 2.11 (0.76-5.84) 0.151 
 Eastern Mediterranean 6 (27.3) 879 (28.6) 1.16 (0.40-3.36) 0.782 
 Other regions 1 (4.5) 241 (7.8) 0.71 (0.09-5.67) 0.744 
 Unknown 0 (0.0) 24 (0.8) n/a 0.998 
a
Immigrants or asylum seekers      
 No 7 (31.8) 1261 (41.1) 1.00  
 Yes, duration <2.5 y 5 (22.7) 1139 (37.1) 0.79 (0.25-2.50) 0.698 
 Yes, illegal immigrants 1 (4.5) 22 (0.7) 8.19 (0.97-69.41) 0.054 
 Yes, duration >2.5 y 5 (22.7) 502 (16.3) 1.79 (0.57-5.68) 0.320 
 Yes, duration unknown 4 (18.2) 147 (4.8) 4.90 (1.42-16.94) 0.012 
Area of living      
 Urban 4 (18.2) 854 (27.8) 1.00  
 Suburban 18 (81.8) 2217 (72.2) 1.73 (0.58-5.14) 0.321 
TB notification and clinical characteristics
 
    
a
Type of case finding     
 Passive 15 (68.2) 1478 (48.1) 1.00  
 Active 2 (9.1) 1511 (49.2) 0.13 (0.03-0.57) 0.007 
 Unknown 5 (22.7) 82 (2.7) 6.01 (2.13-16.93) 0.001 
a
Known TB contacts     
 No 21 (95.5) 2090 (68.1) 9.86 (1.32-73.38) 0.025 
 Yes 1 (4.5) 981 (31.9) 1.00  
Travelling in TB endemic area >3 months     
 No 21 (95.5) 3044 (99.1) 1.00  
 Yes 1 (4.5) 27 (0.9) 5.37 (0.70-41.35) 0.107 
a,b
Site of TB disease      
 PTB 7 (31.8) 1291 (42.0) 1.00  
 EPTB 3 (13.6) 1452 (47.3) 0.38 (0.10-1.48) 0.163 
 PTB + EPTB 12 (54.5) 328 (10.7) 6.75 (2.64-17.27) <0.001 
a,b
Main localisation of TB     
 Lungs 8 (36.4) 1302 (42.4) 1.00  
 CNS 4 (18.2) 49 (1.6) 13.29 (3.87-45.62) <0.001 
 Miliary  6 (27.3) 35 (1.1) 27.90 (9.19-84.70) <0.001 
  
 
 Others 0 (0.0) 1556 (50.7) n/a 0.987 
 Unknown 4 (18.2) 129 (4.2) 5.05 (1.50-16.99) 0.009 
Cavitary TB      
 No 15 (68.2) 2711 (88.3) 1.00  
 Yes 3 (13.6) 231 (7.5) 2.35 (0.67-8.17) 0.180 
 Unknown 4 (18.2) 129 (4.2) 5.60 (1.83-17.12) 0.002 
a
BCG-vaccinated     
 Yes 6 (27.3) 1163 (37.9) 1.00  
 No 5 (22.7) 1167 (38.0) 0.83 (0.25-2.73) 0.760 
 Unknown 11 (50.0) 741 (24.1) 2.88 (1.06-7.81) 0.038 
a
Had TB symptoms     
 No 1 (4.5) 930 (30.3) 1.00  
 Yes 19 (86.4) 1688 (55.0) 10.47 (1.40-78.32) 0.022 
 Unknown 2 (9.1) 453 (14.8) 4.10 (0.37-45.40) 0.249 
Patient’s delay      
 No  1 (4.5) 781 (25.4) 1.00  
 Yes, >1 week 6 (27.3) 1001 (32.6) 4.68 (0.56-38.96) 0.153 
 Unknown 15 (68.2) 1289 (42.0) 9.09 (1.20-68.94) 0.033 
Doctor’s delay      
 No 4 (18.2) 577 (18.8) 1.00  
 Yes, >1 week 6 (27.3) 930 (30.3) 0.93 (0.26-3.31) 0.912 
 Unknown 12 (54.5) 1564 (50.9) 1.11 (0.36-3.44) 0.861 
Total delay (doctor + patient)      
 No  1 (4.5) 103 (3.4) 1.00  
 Yes, >1 week 5 (22.7) 952 (31.0) 0.54 (0.06-4.67) 0.577 
 Unknown 16 (72.7) 2016 (65.6) 0.82 (0.11-6.22) 0.846 
a
Comorbidity      
 No/unknown 16 (72.7) 3031 (98.7) 1.00  
 HIV positive 4 (18.2) 32 (1.0) 23.68 (7.50-74.76) <0.001 
 Malignancy
µ
 2 (9.1) 4 (0.1) 94.72 (16.18-554.44) <0.001 
 Others
µ
 0 (0.0) 4 (0.1) n/a 0.999 
Bacteriological characteristics     
Sputum smear microscopy     
 Negative 3 (13.6) 480 (15.6) 1.00  
 Positive 8 (36.4) 433 (14.1) 2.96 (0.78-11.21) 0.111 
 Unknown/ not done 11 (50.0) 2158 (70.3) 0.82 (0.23-2.93) 0.755 
BAL smear microscopy     
 Negative 2 (9.1) 109 (3.5) 1.00  
 Positive 5 (22.7) 104 (3.4) 2.62 (0.50-13.80) 0.256 
 Unknown/ not done 15 (68.2) 2858 (93.1) 0.29 (0.06-1.27) 0.099 
Mycobacterial culture
 
    
 Negative 1 (4.5) 319 (10.4) 1.00  
 Positive 18 (81.8) 1734 (56.5) 3.31 (0.44-24.89) 0.245 
 Unknown/ not done 3 (13.6) 1018 (33.1) 0.94 (0.10-9.07) 0.957 
Species of Mycobacterium      
 M. tuberculosis 17 (77.3) 1372 (44.7) 1.00  
 Other M. tuberculosis complex 1 (4.5) 79 (2.6) 1.02 (0.13-7.77) 0.984 
 Unknown 4 (18.2) 1620 (52.8) 0.20 (0.07-0.59) 0.004 
Drug susceptibility      
 Confirmed DS-TB 6 (27.3) 552 (18.0) 1.00  
 Presumed DS-TB 14 (63.6) 2365 (77.0) 0.54 (0.21-1.42) 0.215 
 Confirmed DR-TB 2 (9.1) 154 (5.0) 1.19 (0.24-5.98) 0.828 
Treatment characteristics     
a
Previously treated for TB     
 No 13 (59.1) 2796 (91.0) 1.00  
 Yes 2 (9.1) 60 (2.0) 7.17 (1.58-32.47) 0.011 
 Unknown 7 (31.8) 215 (7.0) 7.00 (2.76-17.73) <0.001 
Previously treated for LTBI     
 No 3 (13.6) 970 (31.6) 1.00  
 Yes 0 (0.0) 78 (2.5) n/a 0.997 
  
 
 Unknown 19 (86.4) 2023 (65.9) 3.04 (0.90-10.29) 0.074 
Drug dosing schedule     
 Daily  5 (22.7) 1085 (35.3) 1.00  
 Intermittent
µ
  0 (0.0) 7 (0.2) n/a 0.999 
 Unknown 17 (77.3) 1979 (64.4) 1.86 (0.69-5.07) 0.222 
a,c
Presence of ADR      
 No/unknown 19 (86.4) 2900 (94.4) 1.00  
 Yes, single ADR 1 (4.5) 147 (4.8) 1.04 (0.14-7.81) 0.971 
 Yes, multiple ADRs 2 (9.1) 24 (0.8) 12.72 (2.81-57.66) 0.001 
a,c
Type of ADR     
 No/unknown 19 (86.4) 2900 (94.4) 1.00  
 DILI 2 (9.1) 54 (1.8) 5.65 (1.28-24.87) 0.022 
 Others  1 (4.5) 117 (3.8) 1.30 (0.17-9.83) 0.796 
Treatment interruption >14 days     
 No 4 (18.2) 1045 (34.0) 1.00  
 Yes 0 (0.0) 42 (1.4) n/a 0.998 
 Unknown 18 (81.8) 1984 (64.6) 2.37 (0.80-7.02) 0.119 
a
Hospitalised ≥1 week     
 No/ <1 week 8 (36.4) 2153 (70.1) 1.00  
 Yes 10 (45.5) 815 (26.5) 3.30 (1.30-8.40) 0.012 
 Unknown 4 (18.2) 103 (3.4) 10.45 (3.10-35.27) <0.001 
DOT      
 Yes 6 (27.3) 827 (26.9) 1.00  
 No 16 (72.7) 2240 (72.9) 0.98 (0.38-2.52) 0.974 
 Unknown 0 (0.0) 4 (0.1) n/a 0.999 
 
Data are presented as number (n) with percentages (%), unless stated otherwise: 
#
median with 
interquartile ranges (IQR).  
Abbreviations: ACF, active case finding ; ADR, adverse drug reactions; BAL, bronchoalveolar lavage; 
BCG, Bacillus Calmette-Guerin; CI, confidence interval; CNS, central nervous system; DILI, drug-
induced liver injury; DOT, directly observed therapy; DS-TB, drug-susceptible tuberculosis; DR-TB, 
drug-resistant tuberculosis; E, ethambutol; EPTB, extra-pulmonary tuberculosis; H, isoniazid; HIV, 
human immunodeficiency virus; LTBI, latent tuberculosis infection; n/a, not applicable; OR, odds ratio; 
PCF, passive case finding; PTB, pulmonary tuberculosis; R, rifampicin; Z, pyrazinamide. 
α
Included patients who achieved cure or completed treatment and excluded those who were LTFU or 
with unknown outcomes. 
a
Variables eligible for inclusion in multivariate analysis. 
b,c
Due to the likelihood of collinearity, only one of each of these variables was included during the 
development of the final multivariate model. 
µ




Supplementary table 4. Factors associated with lost to follow-up in children and adolescents treated 








OR (95% CI) P-value 








0.94 (0.92-0.97) <0.001 
a,b
Year of diagnosis     
 1993-1998 67 (41.9) 967 (31.5) 1.00  
 1999-2003 56 (35.0) 877 (28.6) 0.92 (0.64-1.33) 0.662 
 2004-2008 14 (8.8) 456 (14.8) 0.44 (0.25-0.80) 0.007 
 2009-2013 14 (8.8) 371 (12.1) 0.54 (0.30-0.98) 0.043 
 2014-2018 9 (5.6) 400 (13.0) 0.32 (0.16-0.66) 0.002 
a
Age      
 <5 years 24 (15.0) 577 (18.8) 1.28 (0.75-2.18) 0.364 
 5-14 years 34 (21.3) 1046 (34.1) 1.00  
 15-18 years 102 (63.7) 1448 (47.2) 2.17 (1.46-3.22) <0.001 
a
Gender     
 Male 101 (63.1) 1690 (55.0) 1.40 (1.01-1.94) 0.045 
 Female 59 (36.9) 1381 (45.0) 1.00  
a,c
Born in The Netherlands     
 Yes 52 (32.5) 1252 (40.8)   
 No 108 (67.5) 1795 (58.5) 1.45 (1.03-2.03) 0.032 
 Unknown 0 (0.0) 24 (0.8) n/a 0.998 
a,c
WHO Region of birth      
 European 64 (40.0) 1362 (44.4) 1.00  
 African 28 (17.5) 565 (18.4) 1.05 (0.67-1.66) 0.819 
 Eastern Mediterranean 57 (35.6) 879 (28.6) 1.38 (0.96-1.99) 0.085 
 Americas 0 (0.0) 56 (1.8) n/a 0.997 
 South-East Asian 2 (1.3) 79 (2.6) 0.54 (0.13-2.24) 0.395 
 Western Pacific 9 (5.6) 105 (3.4) 1.82 (0.88-3.77) 0.104 
 Unknown 0 (0.0) 25 (0.8) n/a 0.998 
a
Immigrants or asylum seekers      
 No 51 (31.9) 1261 (41.1) 1.00  
 Yes, duration <2.5 y 71 (44.4) 1139 (37.1) 1.54 (1.07-2.23) 0.021 
 Yes, illegal immigrants 8 (5.0) 22 (0.7) 8.99 (3.82-21.17) <0.001 
 Yes, duration >2.5 y 17 (10.6) 502 (16.3) 0.84 (0.48-1.46) 0.533 
 Yes, duration unknown 13 (8.1) 147 (4.8) 2.19 (1.16-4.12) 0.015 
a
Area of living      
 Urban 59 (36.9) 854 (27.8) 1.52 (1.09-2.11) 0.014 
 Suburban 101 (63.1) 2217 (72.2) 1.00  
TB notification and clinical characteristics
 
    
Type of case finding     
 Passive 85 (53.1) 1478 (48.1) 1.00  
 Active 66 (41.3) 1511 (49.2) 0.76 (0.55-1.06) 0.102 
 Unknown 9 (5.6) 82 (2.7) 1.91 (0.93-3.93) 0.079 
a
Known TB contacts     
 No 135 (84.4) 2090 (68.1) 2.53 (1.64-3.91) <0.001 
 Yes 25 (15.6) 981 (31.9) 1.00  
Travelling in TB endemic area >3 months     
 No 158 (98.8) 3044 (99.1) 1.00  
 Yes 2 (1.3) 27 (0.9) 1.43 (0.34-6.05) 0.630 
Site of TB disease      
 PTB 67 (41.9) 1291 (42.0) 1.00  
 EPTB 71 (44.4) 1452 (47.3) 0.94 (0.67-1.33) 0.733 
 PTB + EPTB 22 (13.8) 328 (10.7) 1.29 (0.79-2.12) 0.311 
a
Main localisation of TB     
 Primary TB infection 21 (13.1) 673 (21.9) 0.56 (0.34-0.93) 0.023 
 Lungs 72 (45.0) 1302 (42.4) 1.00  
  
 
 Respiratory tract 16 (10.0) 388 (12.6) 0.75 (0.43-1.30) 0.299 
 CNS 1 (0.6) 49 (1.6) 0.37 (0.05-2.71) 0.327 
 Abdominal 4 (2.5) 51 (1.7) 1.42 (0.50-4.03) 0.512 
 Osteoarticular 5 (3.1) 67 (2.2) 1.35 (0.53-3.45) 0.532 
 Other organs 24 (15.0) 377 (12.3) 1.15 (0.71-1.85) 0.562 
 Miliary  2 (1.3) 35 (1.1) 1.03 (0.24-4.38) 0.965 
 Unknown 15 (9.4) 129 (4.2) 2.10 (1.17-3.77) 0.013 
Cavitary TB      
 No 132 (82.5) 2711 (88.3) 1.00  
 Yes 13 (8.1) 231 (7.5) 1.16 (0.64-2.07) 0.628 
 Unknown 15 (9.4) 129 (4.2) 2.39 (1.36-4.19) 0.002 
BCG-vaccinated     
 Yes 58 (36.3) 1163 (37.9) 1.00  
 No 52 (32.5) 1167 (38.0) 0.89 (0.61-1.31) 0.564 
 Unknown 50 (31.3) 741 (24.1) 1.35 (0.92-2.00) 0.128 
Had TB symptoms     
 No 49 (30.6) 930 (30.3) 1.00  
 Yes 93 (58.1) 1688 (55.0) 1.05 (0.73-1.49) 0.805 
 Unknown 18 (11.3) 453 (14.8) 0.75 (0.43-1.31) 0.316 
Patient’s delay      
 No  46 (28.7) 781 (25.4) 1.00  
 Yes, 1-4 weeks 25 (15.6) 608 (19.8) 0.70 (0.42-1.15) 0.158 
 Yes, 5-8 weeks 12 (7.5) 168 (5.5) 1.21 (0.63-2.34) 0.565 
 Yes, >8 weeks 11 (6.9) 225 (7.3) 0.83 (0.42-1.63) 0.588 
 Unknown 66 (41.3) 1289 (42.0) 0.87 (0.59-1.28) 0.478 
Doctor’s delay      
 No 33 (20.6) 577 (18.8) 1.00  
 Yes, 1-4 weeks 33 (20.6) 556 (18.1) 1.04 (0.63-1.70) 0.884 
 Yes, 5-8 weeks 10 (6.3) 137 (4.5) 1.28 (0.61-2.65) 0.513 
 Yes, >8 weeks 12 (7.5) 237 (7.7) 0.88 (0.45-1.74) 0.725 
 Unknown 72 (45.0) 1564 (50.9) 0.80 (0.53-1.23) 0.315 
Total delay (doctor + patient)      
 No  6 (3.8) 103 (3.4) 1.00  
 Yes, 1-4 weeks 23 (14.4) 332 (10.8) 1.19 (0.47-3.00) 0.714 
 Yes, 5-8 weeks 9 (5.6) 206 (6.7) 0.75 (0.26-2.16) 0.595 
 Yes, >8 weeks 24 (15.0) 414 (13.5) 0.99 (0.40-2.50) 0.992 
 Unknown 98 (61.3) 2016 (65.6) 0.83 (0.36-1.95) 0.676 
Comorbidity      
 No/unknown 158 (98.8) 3031 (98.7) 1.00  
 HIV positive 0 (0.0) 32 (1.0) n.a 0.998 
 Malignancy 1 (0.6) 4 (0.1) 4.80 (0.53-43.16) 0.162 
 Others 1 (0.6) 4 (0.1) 4.80 (0.53-43.16) 0.162 
Bacteriological characteristics     
Sputum smear microscopy     
 Negative 25 (15.6) 480 (15.6) 1.00  
 Positive 18 (11.3) 433 (14.1) 0.80 (0.43-1.48) 0.476 
 Unknown/ not done 117 (73.1) 2158 (70.3) 1.04 (0.67-1.62) 0.859 
BAL smear microscopy     
 Negative 6 (3.8) 109 (3.5) 1.00  
 Positive 3 (1.9) 104 (3.4) 0.52 (0.13-2.15) 0.370 
 Unknown/ not done 151 (94.4) 2858 (93.1) 0.96 (0.41-2.22) 0.924 
Mycobacterial culture
 
    
 Negative 13 (8.1) 319 (10.4) 1.00  
 Positive 104 (65.0) 1734 (56.5) 1.47 (0.82-2.65) 0.198 
 Unknown/ not done 43 (26.9) 1018 (33.1) 1.04 (0.55-1.95) 0.912 
Species of Mycobacterium      
 M. tuberculosis 77 (48.1) 1372 (44.7) 1.00  
 Other M. tuberculosis complex 4 (2.5) 79 (2.6) 0.90 (0.32-2.53) 0.845 
 Unknown 79 (49.4) 1620 (52.8) 0.87 (0.63-0.20) 0.392 
a
Drug susceptibility      
  
 
 Confirmed DS-TB 16 (10.0) 552 (18.0) 1.00  
 Presumed DS-TB 127 (79.4) 2365 (77.0) 1.85 (1.09-3.14) 0.022 
 Confirmed DR-TB 17 (10.6) 154 (5.0) 3.81 (1.88-7.71) <0.001 
Treatment characteristics     
Previously treated for TB     
 No 140 (87.5) 2796 (91.0) 1.00  
 Yes 6 (3.8) 60 (2.0) 2.00 (0.85-4.70) 0.113 
 Unknown 14 (8.8) 215 (7.0) 1.30 (0.74-2.29) 0.363 
Previously treated for LTBI     
 No 29 (18.1) 970 (31.6) 1.00  
 Yes 3 (1.9) 78 (2.5) 1.29 (0.38-4.32) 0.683 
 Unknown 128 (80.0) 2023 (65.9) 2.12 (1.40-3.19) <0.001 
a
Drug dosing schedule     
 Daily  30 (18.8) 1085 (35.3) 1.00  
 Intermittent
µ
  3 (1.9) 7 (0.2) 15.50 (3.82-62.87) <0.001 
 Unknown 127 (79.4) 1979 (64.4) 2.32 (1.55-3.48) <0.001 
a,d
Presence of ADR      
 No/unknown 130 (81.3) 2900 (94.4) 1.00  
 Yes, single ADR 19 (11.9) 147 (4.8) 2.88 (1.73-4.80) <0.001 
 Yes, multiple ADRs 11 (6.9) 24 (0.8) 10.22 (4.90-21.32) <0.001 
a,d
Type of ADR     
 No/unknown 130 (81.3) 2900 (94.4) 1.00  
 DILI 7 (4.4) 54 (1.8) 2.89 (1.29-6.48) 0.010 
 Others 23 (14.4) 117 (3.8) 4.38 (2.71-7.09) <0.001 
a
Treatment interruption >14 days     
 No 20 (12.5) 1045 (34.0) 1.00  
 Yes 10 (6.3) 42 (1.4) 12.44 (5.48-28.23) <0.001 
 Unknown 130 (81.3) 1984 (64.6) 3.42 (2.13-5.51) <0.001 
Hospitalised ≥1 week     
 No/ <1 week 106 (66.3) 2153 (70.1) 1.00  
 Yes 42 (26.3) 815 (26.5) 1.05 (0.73-1.51) 0.807 
 Unknown 12 (7.5) 103 (3.4) 2.37 (1.26-4.44) 0.007 
a
Supervised by PHNs     
 No 12 (7.5) 34 (1.1) 1.00  
 Yes 141 (88.1) 2976 (96.9) 0.13 (0.07-0.26) <0.001 
 Unknown 7 (4.4) 61 (2.0) 0.32 (0.12-0.90) 0.031 
a
DOT      
 Yes 32 (20.0) 827 (26.9) 1.00  
 No 127 (79.4) 2240 (72.9) 1.46 (0.99-2.18) 0.059 
 Unknown 1 (0.6) 4 (0.1) 6.46 (0.70-59.46) 0.099 
 
Data are presented as number (n) with percentages, unless stated otherwise: 
#
median with 
interquartile ranges (IQR). 
Abbreviations: ADR, adverse drug reactions; BAL, bronchoalveolar lavage; BCG, Bacillus Calmette 
Guerin; CI, confidence interval; CNS, central nervous system; DILI, drug-induced liver injury; DOT, 
directly observed therapy; DS-TB, drug-susceptible tuberculosis; DR-TB, drug-resistant tuberculosis; 
E, ethambutol; EPTB, extra-pulmonary tuberculosis; H, isoniazid; HIV, human immunodeficiency virus; 
LTFU, lost to follow-up; LTBI, latent tuberculosis infection; n/a, not applicable; OR, odds ratio; PHNs, 
public health nurses; PTB, pulmonary tuberculosis; R, rifampicin; Z, pyrazinamide. 
£
Included patients who achieved cure or completed treatment and excluded those who died or with 
unknown outcomes. 
a
Variable eligible for inclusion in multivariate analysis. 
b,c,d
Due to the likelihood of collinearity, only one of each of these variables was included during the 
development of the final multivariate model. 
µ
Excluded from multivariate analysis due to the low number of patients (<20).  
  
 
Supplementary table 5. Factors associated with unfavourable outcome in children and adolescents 









OR (95% CI) P-value 








0.95 (0.93-0.96) <0.001 
a,b
Year of diagnosis     
 1993-1998 125 (38.5) 967 (31.5) 1.00  
 1999-2003 128 (39.4) 877 (28.6) 1.13 (0.87-1.47) 0.365 
 2004-2008 29 (8.9) 456 (14.8) 0.49 (0.32-0.75) 0.001 
 2009-2013 27 (8.3) 371 (12.1) 0.56 (0.36-0.87) 0.009 
 2014-2018 16 (4.9) 400 (13.0) 0.31 (0.18-0.53) <0.001 
a
Age      
 <5 years 61 (16.8) 577 (18.8) 1.38 (0.98-1.96) 0.069 
 5-14 years 80 (24.6) 1046 (34.1) 1.00  
 15-18 years 184 (56.6) 1448 (47.2) 1.66 (1.26-2.19) <0.001 
a
Gender     
 Male 203 (62.5) 1690 (55.0) 1.36 (1.07-1.72) 0.011 
 Female 122 (37.5) 1381 (45.0) 1.00  
a,c
Born in The Netherlands     
 Yes 98 (30.2) 1252 (40.8) 1.00  
 No 222 (68.3) 1795 (58.5) 1.58 (1.23-2.03) <0.001 
 Unknown 5 (1.5) 24 (0.8) 2.66 (0.99-7.13) 0.051 
a,c
WHO Region of birth      
 European 118 (36.3) 1362 (44.4) 1.00  
 African 62 (19.1) 565 (18.4) 1.27 (0.92-1.75) 0.151 
 Eastern Mediterranean 117 (36.0) 879 (28.6) 1.54 (1.17-2.01) 0.002 
 Americas 1 (0.3) 56 (1.8) 0.21 (0.03-1.50) 0.119 
 South-East Asian 6 (1.8) 79 (2.6) 0.88 (0.37-2.05) 0.762 
 Western Pacific 16 (4.9) 105 (3.4) 1.76 (1.01-3.07) 0.048 
 Unknown 5 (1.5) 25 (0.8) 2.31 (0.87-6.14) 0.094 
a
Immigrants or asylum seekers      
 No 98 (30.2) 1261 (41.1) 1.00  
 Yes, duration <2.5 y 134 (41.2) 1139 (37.1) 1.51 (1.15-1.99) 0.003 
 Yes, illegal immigrants 17 (5.2) 22 (0.7) 9.94 (5.11-19.34) <0.001 
 Yes, duration >2.5 y 37 (11.4) 502 (16.3) 0.95 (0.64-1.40) 0.791 
 Yes, duration unknown 39 (12.0) 147 (4.8) 3.41 (2.27-5.14) <0.001 
Area of living      
 Urban 85 (26.2) 854 (27.8) 0.92 (0.71-1.19) 0.526 
 Suburban 240 (73.8) 2217 (72.2) 1.00  
TB notification and clinical characteristics
 
    
a
Type of case finding     
 Passive 170 (52.3) 1478 (48.1) 1.00  
 Active 136 (41.8) 1511 (49.2) 0.78 (0.62-0.99) 0.042 
 Unknown 19 (5.8) 82 (2.7) 2.01 (1.19-3.40) 0.009 
a
Known TB contacts     
 No 274 (84.3) 2090 (68.1) 2.52 (1.85-3.43) <0.001 
 Yes 51 (15.7) 981 (31.9) 1.00  
Travelling in TB endemic area >3 months     
 No 321 (98.8) 3044 (99.1) 1.00  
 Yes 4 (1.2) 27 (0.9) 1.40 (0.49-4.04) 0.528 
a,d
Site of TB disease      
 PTB 163 (50.2) 1291 (42.0) 1.00  
 EPTB 118 (36.3) 1452 (47.3) 0.64 (0.50-0.82) 0.001 
 PTB + EPTB 44 (13.5) 328 (10.7) 1.06 (0.74-1.51) 0.737 
a,d
Main localisation of TB     
 Primary TB infection 30 (9.2) 673 (21.9) 0.54 (0.36-0.82) 0.004 
 Lungs 107 (32.9) 1302 (42.4) 1.00  
  
 
 Respiratory tract 18 (5.5) 388 (12.6) 0.56 (0.34-0.94) 0.029 
 CNS 7 (2.2) 49 (1.6) 1.74 (0.77-3.93) 0.184 
 Abdominal 6 (1.8) 51 (1.7) 1.43 (0.60-3.41) 0.418 
 Osteoarticular 6 (1.8) 67 (2.2) 1.09 (0.46-2.57) 0.844 
 Other organs 33 (10.2) 377 (12.3) 1.06 (0.71-1.60) 0.761 
 Miliary  9 (2.8) 35 (1.1) 3.13 (1.46-6.68) 0.003 
 Unknown 109 (33.5) 129 (4.2) 10.28 (7.45-14.19) <0.001 
Cavitary TB      
 No 197 (60.6) 2711 (88.3) 1.00  
 Yes 19 (5.8) 231 (7.5) 1.13 (0.69-1.85) 0.620 
 Unknown 109 (33.5) 129 (4.2) 11.63 (8.67-15.59) <0.001 
BCG-vaccinated     
 Yes 117 (36.0) 1163 (37.9) 1.00  
 No 107 (32.9) 1167 (38.0) 0.91 (0.69-1.20) 0.508 
 Unknown 101 (31.1) 741 (24.1) 1.35 (1.02-1.80) 0.035 
Had TB symptoms     
 No 93 (28.6) 930 (30.3) 1.00  
 Yes 199 (61.2) 1688 (55.0) 1.18 (0.91-1.53) 0.213 
 Unknown 33 (10.2) 453 (14.8) 0.73 (0.48-1.10) 0.132 
Patient’s delay      
 No  88 (27.1) 781 (25.4) 1.00  
 Yes, 1-4 weeks 54 (16.6) 608 (19.8) 0.79 (0.55-1.12) 0.189 
 Yes, 5-8 weeks 24 (7.4) 168 (5.5) 1.27 (0.78-2.05) 0.334 
 Yes, >8 weeks 24 (7.4) 225 (7.3) 0.95 (0.59-1.52) 0.821 
 Unknown 135 (41.5) 1289 (42.0) 0.93 (0.70-1.23) 0.612 
Doctor’s delay      
 No 56 (17.2) 577 (18.8) 1.00  
 Yes, 1-4 weeks 72 (22.2) 556 (18.1) 1.33 (0.92-1.93) 0.125 
 Yes, 5-8 weeks 19 (5.8) 137 (4.5) 1.43 (0.82-2.48) 0.206 
 Yes, >8 weeks 21 (6.5) 237 (7.7) 0.91 (0.54-1.54) 0.733 
 Unknown 157 (48.3) 1564 (50.9) 1.03 (0.75-1.42) 0.836 
Total delay (doctor + patient)      
 No  9 (2.8) 103 (3.4) 1.00  
 Yes, 1-4 weeks 40 (12.3) 332 (10.8) 1.38 (0.65-2.94) 0.405 
 Yes, 5-8 weeks 20 (6.2) 206 (6.7) 1.11 (0.49-2.53) 0.802 
 Yes, >8 weeks 49 (15.1) 414 (13.5) 1.35 (0.64-2.85) 0.423 
 Unknown 207 (63.7) 2016 (65.6) 1.17 (0.59-2.36) 0.650 
a
Comorbidity      
 No/unknown 314 (96.6) 3031 (98.7) 1.00  
 HIV positive 7 (2.2) 32 (1.0) 2.11 (0.92-4.82) 0.076 
 Malignancy
µ
 3 (0.9) 4 (0.1) 7.24 (1.61-32.49) 0.010 
 Others 1 (0.3) 4 (0.1) 2.41 (0.27-21.66) 0.431 
Bacteriological characteristics     
Sputum smear microscopy     
 Negative 58 (17.8) 480 (15.6) 1.00  
 Positive 46 (14.2) 433 (14.1) 0.88 (0.58-1.32) 0.536 
 Unknown/ not done 221 (68.0) 2158 (70.3) 0.85 (0.62-1.15) 0.289 
BAL smear microscopy     
 Negative 16 (4.9) 109 (3.5) 1.00  
 Positive 15 (4.6) 104 (3.4) 0.98 (0.46-2.09) 0.964 




    
 Negative 21 (6.5) 319 (10.4) 1.00  
 Positive 187 (57.5) 1734 (56.5) 1.64 (1.03-2.61) 0.038 
 Unknown/ not done 117 (36.0) 1018 (33.1) 1.75 (1.08-2.82) 0.023 
a,e
Species of Mycobacterium      
 M. tuberculosis 151 (46.5) 1372 (44.7) 1.00  
 M. bovis 5 (1.5) 18 (0.6) 2.52 (0.92-6.89) 0.071 
 Other M. tuberculosis complex 3 (0.9) 61 (2.0) 0.45 (0.14-1.44) 0.178 




Drug susceptibility      
 Confirmed DS-TB 39 (12.0) 552 (18.0) 1.00  
 Presumed DS-TB 260 (80.0) 2365 (77.0) 1.56 (1.10-2.21) 0.013 
 Confirmed DR-TB 26 (8.0) 154 (5.0) 2.39 (1.41-4.05) 0.001 
Treatment characteristics     
a
Previously treated for TB     
 No 273 (84.0) 2796 (91.0) 1.00  
 Yes 13 (4.0) 60 (2.0) 2.22 (1.20-4.09) 0.011 
 Unknown 39 (12.0) 215 (7.0) 1.86 (1.29-2.67) 0.001 
Previously treated for LTBI     
 No 54 (16.6) 970 (31.6) 1.00  
 Yes 4 (1.2) 78 (2.5) 0.92 (0.32-2.61) 0.877 
 Unknown 267 (82.2) 2023 (65.9) 2.37 (1.75-3.21) <0.001 
a
Drug dosing schedule     
 Daily  56 (17.2) 1085 (35.3) 1.00  
 Intermittent
µ
  3 (0.9) 7 (0.2) 8.30 (2.09-32.97) 0.003 
 Unknown 266 (81.8) 1979 (64.4) 2.60 (1.93-3.51) <0.001 
a,f
Presence of ADR      
 No/unknown 291 (89.5) 2900 (94.4) 1.00  
 Yes, single ADR 20 (6.2) 147 (4.8) 1.36 (0.84-2.20) 0.216 
 Yes, multiple ADRs 14 (4.3) 24 (0.8) 5.81 (2.97-11.36) <0.001 
a,f
Type of ADR     
 No/unknown 291 (89.5) 2900 (94.4) 1.00  
 DILI 9 (2.8) 54 (1.8) 1.66 (0.81-3.40) 0.165 
 Others 25 (7.7) 117 (3.8) 2.13 (1.36-3.33) 0.001 
a
Treatment interruption >14 days     
 No 42 (12.9) 1045 (34.0) 1.00  
 Yes 11 (3.4) 42 (1.4) 6.52 (3.13-13.55) <0.001 
 Unknown 272 (83.7) 1984 (64.6) 3.41 (2.44-4.76) <0.001 
a
Hospitalised ≥1 week     
 No/ <1 week 238 (73.2) 2153 (70.1) 1.00  
 Yes 68 (20.9) 815 (26.5) 0.75 (0.57-1.00) 0.050 
 Unknown 19 (5.8) 103 (3.4) 1.67 (1.01-2.77) 0.048 
a
Supervised by PHNs     
 No 32 (9.8) 34 (1.1) 1.00  
 Yes 192 (59.1) 2976 (96.9) 0.07 (0.04-0.11) <0.001 
 Unknown 101 (31.1) 61 (2.0) 1.76 (0.99-3.14) 0.055 
a
DOT      
 Yes 50 (15.4) 827 (26.9) 1.00   
 No 271 (83.4) 2240 (72.9) 2.00 (1.46-2.73) <0.001 
 Unknown 4 (1.2) 4 (0.1) 16.54 (4.02-68.09) <0.001 
 
Data are presented as number (n) with percentages, unless stated otherwise: 
#
median with 
interquartile ranges (IQR).  
Abbreviations: ADR, adverse drug reactions; BAL, bronchoalveolar lavage; BCG, Bacillus Calmette 
Guerin; CI, confidence interval; CNS, central nervous system; DILI, drug-induced liver injury; DOT, 
directly observed therapy; DS-TB, drug-susceptible tuberculosis; DR-TB, drug-resistant tuberculosis; 
E, ethambutol; EPTB, extra-pulmonary tuberculosis; H, isoniazid; HIV, human immunodeficiency virus; 
LTBI, latent tuberculosis infection; OR, odds ratio; PHNs, public health nurses; PTB, pulmonary 
tuberculosis; R, rifampicin; Z, pyrazinamide. 
β
The sum of patients who achieved cure or completed treatment. 
¥
The sum of patients who died, were LTFU, or with unknown outcomes. 
a
Variable eligible for inclusion in multivariate analysis. 
b,c,d,e,f
Due to the likelihood of collinearity, only one of each of these variables was included during the 
development of the final multivariate model. 
µ
Excluded from multivariate analysis due to the low number of patients (<20).  
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